Vertex Versus NHS England: Was The Stand-Off Worth It?
Real World Evidence Key To CF Deal
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?
You may also be interested in...
It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
The US FDA cleared the combination in just three months for patients with the most common genetic mutation. Company sets price above double regimen Symdeko, but in line with trailblazer Kalydeco.